Giampaolo Bianchini
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 155 publications
TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10.
Journal: Future oncology (London, England)
Published: July 31, 2026
Netupitant versus aprepitant: model-predicted neurokinin-1 receptor occupancy and implications for long-delayed nausea and vomiting prevention.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: July 22, 2026
Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 14, 2026
SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.
Journal: The oncologist
Published: May 22, 2026
SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.
Journal: The oncologist
Published: May 22, 2026
The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions.
Journal: Cancer treatment reviews
Published: April 28, 2026
Time-dependent prognostic impact of tumor grade in stage I-III breast cancers.
Journal: ESMO open
Published: April 27, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: April 24, 2026
Diagnostic accuracy of modern imaging following neoadjuvant therapy for breast cancer: a comparative analysis of ultrasound versus [18F] FDG PET/MRI in breast response assessment.
Journal: Frontiers in oncology
Published: April 01, 2026
Analysis of Large Language Model Decision Making in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
Journal: JCO clinical cancer informatics
Published: March 06, 2026
Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.
Journal: Breast (Edinburgh, Scotland)
Published: February 12, 2026
Last Updated: 09/26/2026